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REPORT
Enhanced Maternal Origin of the 22q11.2 Deletion
in Velocardiofacial and DiGeorge Syndromes
Maria Delio,1 Tingwei Guo,1 Donna M. McDonald-McGinn,2,3 Elaine Zackai,2,3,4 Sean Herman,1
Mark Kaminetzky,1 Anne Marie Higgins,5 Karlene Coleman,6,7 Carolyn Chow,8 Maria Jarlbrzkowski,8
Carrie E. Bearden,8 Alice Bailey,2,3 Anders Vangkilde,9 Line Olsen,9 Charlotte Olesen,10
Flemming Skovby,11 Thomas M. Werge,9 Ludivine Templin,11 Tiffany Busa,11 Nicole Philip,12
Ann Swillen,13 Joris R. Vermeesch,13 Koen Devriendt,13 Maude Schneider,14 Sophie Dahoun,14
Stephan Eliez,14 Kelly Schoch,15 Stephen R. Hooper,16,17 Vandana Shashi,15 Joy Samanich,18
Robert Marion,18 Therese van Amelsvoort,19 Erik Boot,20 Petra Klaassen,21 Sasja N. Duijff,21
Jacob Vorstman,22 Tracy Yuen,23 Candice Silversides,23 Eva Chow,23 Anne Bassett,23 Amos Frisch,24
Abraham Weizman,25 Doron Gothelf,25,26 Maria Niarchou,27 Marianne van den Bree,27
Michael J. Owen,27 Damian Heine Sun˜er,28 Jordi Rosell Andreo,28 Marco Armando,29 Stefano Vicari,29
Maria Cristina Digilio,30 Adam Auton,31 Wendy R. Kates,32 Tao Wang,33 Robert J. Shprintzen,5
Beverly S. Emanuel,2,3,4 and Bernice E. Morrow1,34,*
Velocardiofacial and DiGeorge syndromes, also known as 22q11.2 deletion syndrome (22q11DS), are congenital-anomaly disorders
caused by a de novo hemizygous 22q11.2 deletion mediated by meiotic nonallelic homologous recombination events between low-
copy repeats, also known as segmental duplications. Although previous studies exist, each was of small size, and it remains to be
determined whether there are parent-of-origin biases for the de novo 22q11.2 deletion. To address this question, we genotyped a total
of 389 DNA samples from 22q11DS-affected families. A total of 219 (56%) individuals with 22q11DS hadmaternal origin and 170 (44%)
had paternal origin of the de novo deletion, which represents a statistically significant bias for maternal origin (p ¼ 0.0151). Combined
withmany smaller, previous studies, 465 (57%) individuals hadmaternal origin and 345 (43%) had paternal origin, amounting to a ratio
of 1.35 or a 35% increase in maternal compared to paternal origin (p ¼ 0.000028). Among 1,892 probands with the de novo 22q11.2
deletion, the average maternal age at time of conception was 29.5, and this is similar to data for the general population in individual
countries. Of interest, the female recombination rate in the 22q11.2 region was about 1.6–1.7 times greater than that for males, suggest-
ing that for this region in the genome, enhanced meiotic recombination rates, as well as other as-of-yet undefined 22q11.2-specific
features, could be responsible for the observed excess in maternal origin.
Velocardiofacial (MIM 192430) and DiGeorge (MIM
188400) syndromes, also known as 22q11.2 deletion
syndrome (22q11DS), are congenital-malformation disor-
ders most often associated with a de novo 3 Mb hemizy-
gous 22q11.2 deletion.1,2 Smaller nested deletions occur
in 5%–10% of individuals, and all have similar pheno-
types.3,4 The frequency of the syndromes is estimated to
be 1/4,000 live births, making them among the most
1Departments of Genetics, Pediatrics, andObstetrics &Gynecology andWomen’s Health, Albert Einstein College ofMedicine, Bronx, NY 10461, USA; 2Divi-
sion of HumanGenetics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA; 3Department of Pediatrics, University of Pennsylvania School of
Medicine, Philadelphia, PA 19104, USA; 4Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA;
5The Virtual Center for Velo-Cardio-Facial Syndrome, Manlius, NY 13104, USA; 6Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA; 7Nell Hodgson
Woodruff School of Nursing, Emory University, Atlanta, GA 30322, USA; 8Department of Psychiatry and Biobehavioral Sciences and Department of
Psychology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA 90095, USA; 9Institute of Bio-
logical Psychiatry, Mental Health Center Sct. Hans, University of Copenhagen, Copenhagen 4000, Denmark; 10Department of Pediatrics, Aarhus University
Hospital, Aarhus 8000, Denmark; 11Department of Clinical Genetics, Copenhagen University Hospital, Copenhagen 2100, Denmark; 12Hoˆpital de la
Timone, Assistance Publique – Hoˆpitaux de Marseille, Marseille 13005, France; 13Center for Human Genetics, University Hospital Gasthuisberg, University
of Leuven, Leuven 03000, Belgium; 14Office Me´dico-Pe´dagogique Research Unit, Department of Psychiatry, University of Geneva School of Medicine,
Geneva 1211, Switzerland; 15Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC 27705, USA; 16Depart-
ment of Psychiatry and The Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine, Chapel Hill, NC 27514,
USA; 17Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27705, USA; 18Department of Pediatrics, Monte-
fiore Medical Center, Bronx, NY 10461, USA; 19Department of Psychiatry and Psychology, University of Maastricht, Maastricht 6211, the Netherlands;
20Department of Psychiatry, Academic Medical Centre, Amsterdam 1100, the Netherlands; 21Department of Pediatric Psychology, University Medical
Center Utrecht, Utrecht 3584, the Netherlands; 22Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht,
Utrecht 3584, the Netherlands; 23Center for Addiction andMental Health, University of Toronto, Toronto, ONM5T 1R8, Canada; 24The FelsensteinMedical
Research Center, Petah Tikva 49100, Israel; 25The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; 26The Edmond and Lily Safra
Children’s Hospital, Sheba Medical Center, Tel Hashomer 52621, Israel; 27Medical Research Council Centre for Neuropsychiatric Genetics & Genomics
and the Neuroscience & Mental Health Research Institute, Cardiff University, Cardiff CF14 4XN, UK; 28Laboratory of Molecular Genetics, Department
of Genetics, University Hospital Son Espases, Palma de Mallorca 07020, Spain; 29Child Neuropsychiatry Unit, Department of Neuroscience, Bambino
Gesu` Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome 00165, Italy; 30Medical Genetic Unit, Department of Pediatrics, Bambino
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common congenital-malformation syndromes in hu-
mans.5–10 The de novo 22q11.2 deletion usually results
from nonallelic homologous recombination (NAHR)
events between flanking low-copy repeats (LCRs), also
known as segmental duplications (SDs), termed
LCR22s.3,4,11,12 NAHR-frequency-altering genetic risk
factors, such as parent-of-origin bias or maternal age,
have not been defined for 22q11DS. This might partly be
because such factors are infrequent and tend not to be
apparent within individual nuclear families. In addition,
previous studies were all of small sample size. If gender
bias did occur, it might suggest particular vulnerabilities
in meiotic machinery.
In this study, we isolated or obtained DNA samples from
451 individuals with 22q11DS and their healthy parents
after receiving their informed consent (internal review
board 1999-201). All procedures were in accordance with
the ethical standards of the Albert Einstein College of
Medicine Committee on Clinical Investigation. The
22q11.2 deletion size was determined by multiplex liga-
tion-dependent probe amplification (MLPA) testing
(SALSA MLPA Kit P250 DiGeorge probemix, Medical
Research Council Holland, the Netherlands) or microsatel-
lite-marker analysis.11,13,14 We used several molecular
biological methods to detect the parent from whom the
de novo deletion originated. Initially, we performed
haplotype analysis by using microsatellite markers on
115 families.11,13,14We subsequently performed SNP-based
genotyping with SNPs spanning the 3 Mb 22q11.2 region
by using Sequenom MassArray technology (Tables S1and
S2, available online). A representative example of results
obtained with both microsatellite and SNP markers is
shown in Figure 1. The map positions of the microsatellite
and SNP genetic markers spanning the 3 Mb interval are
shown in Figure 2. A subset of the SNP genotypes was
validated with traditional Sanger sequencing (Figure 1
and Figure S1).
There were examples where the genotyping data were
uninformative or only one SNP was informative as to
parental origin of the de novo 22q11.2 deletion
(Table S2). In these cases, we used Sequenom data that
were available from the TBX1 (MIM 602054) locus on
22q11.215 (Table S3). In addition, we performed Sanger
sequencing to correct genotypes in 40 of the 45 probands
with heterozygous SNP miscalls (Table S2; primers are
indicated in Table S4).
Using this combination of approaches, we were able to
obtain informative results for 389 (86.2%) of 451 families.
The main reason for the lack of informative genetic data
for the remaining 62 subjects was either missing parental
DNA samples or poor DNA quality.
We found that the de novo deletion was of maternal
origin in 219 (56.3%) of the probands and of paternal
origin in 170 (43.7%) of the probands. We performed the
binomial test for equal proportions to compare the actual
parental origin of the deletion with the null hypothesis
(proportion equal to 50%). There was a statistically signif-
icant maternal bias for the parent of origin of the 22q11.2
deletion (p ¼ 0.015; ‘‘Current study’’ in Figure 3).
Previous studies of parent of origin of the de novo
22q11.2 deletion were relatively small in size (<100
probands; Table S5) and hence might have been under-
powered. We used Fisher’s combined probability test to
calculate the combined p value from these previous
Figure 1. Haplotype Analysis for Family 12
Both microsatellite and SNP genotype analysis was performed on
DNA from the female proband (BM69), her mother (BM70),
and her father (BM71). The vertical lines represent the 22q11.2
region. Informative markers are highlighted in blue. Images of
sequences 1 and 2 are from Sanger-sequencing chromatograms
of markers rs2871041 and rs178084, respectively. Sequence 1 illus-
trates noninformative genotypes, whereas sequence 2 confirms
informative genotypes. For example, for rs178084, the genotypes
indicate that the paternal genotype is T/C and the maternal geno-
type is C/C. The child displays a T allele, which was inherited
through the father, identifying the deletion as being maternal in
origin. The following abbreviation is used: NC, no SNP call (failed
genotype).
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studies. We ensured that these comprised different DNA
samples to those used in our current studies (exceptions
are noted in Table S5). When we combined our data with
those from these previous studies, we found that there
were 465 (57.4%) individuals in whom the de novo dele-
tion was of maternal origin and 345 (42.6%) in whom
the deletion was of paternal origin (two-tailed binomial
test, p ¼ 0.00065; Figure 3). The combined results were
highly significant with the use of Fisher’s combined prob-
ability test (p ¼ 0.000028)—the ratio of maternal to
paternal origin was 1.35 to 1.00, corresponding to a 35%
increase in risk for maternal compared to paternal origin
of the de novo 22q11.2 deletion.
A possible limitation of this and other similar studies is a
sampling bias in which DNA samples from fathers might
be disproportionally missing from the cohort available
for study. Fortunately, DNA samples from both parents
were available in themajority of families. Second, we could
still determine parent of origin of the deletion in those
families with missing DNA samples from fathers given
informative genotypes from the respective proband and
mother. The numbers of families for which genotypes for
parent of origin were uninformative were too low for
drawing conclusions with respect to such a sampling bias.
The incidence of whole-chromosome aneuploidy
increases with increasing maternal age in the general pop-
ulation. We were therefore interested to see whether a
similar increase in maternal age is linked to the de novo
22q11.2 deletion and could thus explain our findings.
We first went to the website of the United Nations Fertility
and Family Planning Section of the Department of
Economic and Social Affairs (DESA) Population Division
(Web Resources) and obtained control data (‘‘Mean Age
at Childbearing’’ section under ‘‘Period Fertility Indica-
tors’’) for 11 countries. The epidemiological data for each
country are indicated in Table 1. Data for the 22q11DS
cohort are presented in Table 2 and Figure 4A. We evalu-
ated the parental age at time of conception for 1,892
mothers and 1,809 fathers of individuals with the de
Figure 2. Genetic Markers Used for Genotyping 22q11DS Trios
AUCSCGenome Browser (hg19) image of the 22q11.21–q11.22 genomic region relevant to this study. The image displays representative
genes spanning the region for orientation, as well as 15 microsatellite and 28 SNP markers used for our study. The positions of LCRs, or
SDs, taken from the SD track and 1.5, 2.0, and 3.0 Mb deletions in 22q11.2 are also illustrated.
Figure 3. A Maternal Bias Occurs in the Origin of the 22q11.2
Deletion
The bar graph shows the number of 22q11DS individuals with
either maternal or paternal origin of the deletion. Light gray
data bars represent the amount of maternal, paternal, and
combined deletion origin from previous studies (Table S5). Dark
gray data bars represent the amount of maternal, paternal, and
combined deletion origin from the current study (Table S2). Black
data bars represent the total amount of maternal and paternal
deletion origin from the combined previous and current data
sets. The two-tailed p value is listed below the figure. Significance
is based on a p value < 0.05.
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novo 22q11.2 deletion. On the basis of the data presented
in Table 2 and Figure 4A, we found that the mean age is
29.5 years for mothers (n ¼ 1,891) and 32.4 years for
fathers (n ¼ 1,809).
We used the one-sample t test to compare the mean
childbearing age of the mothers of 22q11DS children
with the mean childbearing age of the general population
(see Web Resources) and stratified this by country (Table 1
and Figure 4B). To combine data from different countries,
we applied both fixed-effects and random-effects models
for the meta-analysis. The fixed-effects model assumes
that there is no heterogeneity among countries, whereas
the random-effects model does not. Under the fixed-effects
model, all countries were estimated with the assumption of
the same effect size (difference of maternal age), and so
weights were assigned to countries on the basis of the
number of families for each country. The random-effects
model did not assume the same difference for all countries.
On the basis of the results from both methods, we found
no statistically significant difference between the child-
bearing age for mothers of 22q11DS offspring and that
for the general population (Table 3). Thus, these results
do not support a hypothesis of advanced maternal age as
an etiologic factor for the finding of enhanced maternal
origin of the deletion. General population data were not
available for paternal age at the time of conception. None-
theless, we provide the paternal ages of fathers of 22q11DS
offspring for all countries in our study (Table S6).We found
comparable paternal and maternal ages (Figure S2).
Next, on the basis of the hypothesis that enhanced
maternal origin of the deletion might be a result of
increased female recombination rate in the 22q11.2
region, we considered the known female and male recom-
bination rates across chromosome 22 to explain the
maternal bias found. According to classic genetic studies,
it was shown that the female autosomal genetic-map
length is 1.6- to 1.7-fold greater than the male genetic
length and that chromosome 22 shows relatively typical
results.16–21 Figure 5 shows a summary of recombination
rates for the 22q11.2 region. The recombination rate
(cM/Mb) has been previously determined by the genotyp-
ing of multigenerational families with the use of microsa-
tellite markers,16,17,19 and a summary of the data from
the UCSC Genome Browser is shown in Figure 5B. Skewing
Table 2. Maternal Age Ranges at Childbirth in the 22q11DS Cohort
Country
Number of Mothers in Specified Age Ranges
Total15–19 Years 20–24 Years 25–29 Years 30–34 Years 35–39 Years 40–44 Years 45–49 Years
United States 24 136 271 286 133 32 2 884
Denmark 2 6 20 18 9 1 0 56
France 3 17 27 34 5 5 0 91
Switzerland 3 12 45 42 9 2 0 113
Belgium 1 18 46 27 11 0 0 103
Netherlands 2 20 68 91 37 1 1 220
Spain 1 3 7 13 1 0 0 25
Canada 3 29 53 44 17 0 0 146
United Kingdom 1 5 23 36 17 2 0 84
Italy 3 13 29 30 14 6 0 95
Israel 3 16 21 27 8 0 0 75
Total 46 275 610 648 261 49 3 1,892
The number of mothers in each age range from each country is shown. The total number of mothers analyzed (1,892) is listed at the bottom of the rightmost
column.
Table 1. Number of 22q11DS-Affected Families Organized by
Country
Country
Number of 22q11DS-Affected Families
Maternal Origin Paternal Origin
United States 884 822
Denmark 56 54
France 91 87
Switzerland 113 114
Belgium 103 102
Netherlands 220 213
Spain 25 23
Canada 146 144
United Kingdom 84 81
Italy 95 95
Israel 75 74
Total 1,892 1,809
We obtained data from individual 22q11DS-affected families in which both
parents were healthy and the affected child harbored a de novo 22q11.2 dele-
tion. The data are sorted by country.
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of recombination rate is consistent with more recent find-
ings for parent-offspring pairs analyzed with high-density
SNP markers, which indicate that the female-to-male
map-distance ratio is 2.31 for chromosomal region
22q11.2 and 1.46 for all of chromosome 22 (Figure 5C).22
These data suggest that there is an increase in the maternal
meiotic recombination rate in the 22q11.2 region. If this
is true, it might suggest that the 22q11.2 duplication
(MIM 608363) might also originate more often from
maternal de novo events. There are three complicating
features that might make testing this hypothesis difficult:
first, the 22q11.2 duplication is frequently inherited;
second, the penetrance is reduced; and third, the expres-
sivity is variable. Thus, it might be difficult to obtain the
number of subjects needed for an adequately powered
statistical study.
To determine whether our finding could be broadly
applicable to other types of chromosomal-rearrangement
disorders, we examined similar data in the available litera-
ture. In one study of 876 cases of any de novo chromo-
somal-rearrangement disorder (independent of whether it
occurred byNAHRmechanisms), 464 (53%) had amaternal
Figure 4. Range of Maternal Age at
Childbirth
(A) Range ofmaternal age at childbirth. For
each age range, determined from the
values shown in Table 2, light gray bars
indicate the percentage of mothers who
gave birth to a 22q11DS child.
(B) Average maternal age at childbirth per
country for 22q11DS offspring and normal
population controls. The average maternal
age for 22q11DS offspring was derived
from the data shown in Table 2. *Control
data were derived from the United Nations
DESA Population Division World Fertility
Data, 2008 (Web Resources).
origin of the deletion and 412 (47%)
had a paternal origin of a deletion,
suggesting a marginal maternal bias
(p ¼ 0.04).23 In a similar study of
115 individuals with de novo rear-
rangements found by karyotypic
analysis, there was a paternal bias24
(83/115 [72%]). In addition, there
was a significant paternal bias for
de novo structural variations by any
mechanism in 118 individuals with
intellectual disability as identified
by array comparative genome hybrid-
ization.25 Notably, these studies
included various types of structural
variations.
In one recent study of parent of
origin of NAHR-mediated rearrange-
ments irrespective of genomic loca-
tion, it was found that 12 of 30 were
of maternal origin and 13 of 71 were of paternal origin.26
Neurofibromatosis type 1 (NF1 [MIM 162200]) is caused
by either deletions or mutations in NF1 (MIM 613113) in
17q11.2. The NF1 deletion results from NAHR events
during meiosis. A strong maternal bias exists for the NF1
deletion, but studies were small in size.27,28 For Williams
Beuren syndrome (WBS [MIM 194050]), which results
fromNAHR events between flanking LCRs, or SDs, in chro-
mosomal region 7q11.23, we performed a meta-analysis
on existing data29–33 and found no gender bias of origin
for the 7q11.23 deletion among 471 probands: 248
(53%) were of maternal origin and 223 (47%) were of
paternal origin (two-tailed p ¼ 0.27). There is, however,
an important confounding feature for WBS in that
the presence of an inversion polymorphism32 greatly
increases risk of meiotic NAHR events.34–36 No such
inversion polymorphism exists in 22q11.2.37 In contrast,
in one study of 61 probands with Charcot-Marie-Tooth
type 1 (CMT1A [MIM 118220]; 17p11.2–p12), there was
a distinct bias for paternal origin of the de novo CMT1A
duplication,23 implying a different mechanism for this
rearrangement.
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Another factor for consideration is that the recombina-
tion rate is reduced in centromeric regions and increased
in the telomeric regions of chromosomes.38 In previous
studies using restriction fragment polymorphic39 or micro-
satellite markers16,17 and newer studies using SNP
markers,18,19 it was determined that the average female
recombination rate is 1.6–1.7 for the 22q11.2 region and
throughout the genome. This suggests that there is
a maternal bias for recombination within the 22q11.2
region, despite its location near the centromere. The
same is true for the NF1 region on 17p11.2, where the
maternal bias for origin of the de novo deletion is similar
to the enhanced female-to-male recombination-rate ratio.
The similar skewing of the female-to-male recombina-
tion-rate ratio on 17p11.2 and the absence of gender bias
of origin for the 7q11.23 deletion indicate that it is not
possible to generalize that NAHR events depend solely on
such recombination-rate factors.
This leads to the conclusion that there might be partic-
ular features that enhance the vulnerability of the
22q11.2 region in females rather than males, in addition
to the known differences in gender-based meiotic
machinery. An altered number of crossovers can lead to
chromosomal aneuploidies, particularly in female
meiosis.40 In a small haplotype-reconstruction study of
20 families for which DNA samples from three generations
of individuals were available, there were an unexpectedly
higher number of typical interchromosomal exchanges
in the pter–q11.2 region between chromosome 22 homo-
logs than in the rest of the chromosome and other pter–
q11 regions on other chromosomes.41 This suggests that
the 22q11.2 region might be particularly susceptible to
recombination during meiosis and that there might be
gender biases based in part upon differences in meiotic
processes. The two LCR22s that flank the typical 3Mb dele-
tion are over 250 kb in size. Recently, it has been suggested
that NAHR events result from ectopic chromosome
synapsis and that the likelihood of these events might
increase with increased LCR length.42 Our data suggest
that, in addition, there might be gender-specific biases in
synapsis formation during meiosis.
Recent studies have compiled catalogs of rare copy-
number variations (CNVs) in congenital-anomaly and
developmental-delay disorders and have underscored their
clinical importance.43,44 In some cases, there might be
a second pathogenic CNV that could help to explain the
variable penetrance and expressivity of associated pheno-
types.44 Further studies will be needed for more fully
understanding the molecular mechanisms responsible for
the etiology of the de novo mutations involved and the
molecular basis of their variable phenotypic expression.
Supplemental Data
Supplemental Data include two figures and six tables and can be
found with this article online at http://www.cell.com/AJHG.
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Web Resources
The URLs for data presented herein are as follows:
Online Mendelian Inheritance in Man (OMIM), http://omim.org/
UCSC Human Genome Browser, http://genome.ucsc.edu/cgi-bin/
hgGateway
United Nations DESA Population Division Word Fertility Data
2008, http://www.un.org/esa/population/publications/WFD%
202008/WP_WFD_2008/Data.html
Table 3. Maternal Age Statistics
Countries Difference of Mean Age [95% CI]
Denmark 0.2821 [1.5993, 1.0350]
France 1.0791 [2.2300, 0.0717]
United States 1.7425 [ 1.3810, 2.1041]
Switzerland 1.4168 [2.2673, 0.5663]
Belgium 2.3175 [3.1176, 1.5173]
Netherlands 0.7182 [1.3066, 0.1298]
Spain 2.3800 [4.2015, 0.5585]
Canada 1.3329 [2.0551, 0.6106]
United Kingdom 2.1500 [ 1.1920, 3.1080]
Italy 1.0895 [2.2444, 0.0654]
Israel 1.7333 [2.9001, 0.5666]
All Countries Combined
Fixed-effects model 0.0858 [0.1400, 0.3116]a
Random-effects model 0.7330 [1.8078, 0.3418]b
Data are based on the United Nations World Fertility Data, 2008 (see Web
Resources). The difference between the mean childbearing age of mothers of
22q11DS individuals and that of the general population is shown as sorted
by country. The following abbreviation is used: CI, confidence interval.
aZ score ¼ 0.7447; p value ¼ 0.4565.
bZ score ¼ –1.3367; p value ¼ 0.1813.
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